SCHEMBL5664992

SCHEMBL5664992

CCCN(CC)C(=O)C(N)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ TP53 P04637 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ SLC6A2 P23975 1/20 0.43
▸ SLC6A4 P31645 1/20 0.43
▸ NPSR1 Q6W5P4 3/20 0.42
▸ KMT2A Q03164 3/20 0.42
▸ OPRD1 P41143 3/20 0.42
▸ HTT P42858 2/20 0.42
▸ MEN1 O00255 2/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ GLA P06280 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ RECQL P46063 1/20 0.41
▸ LMNA P02545 4/20 0.41
▸ MAPT P10636 3/20 0.41
▸ TDP1 Q9NUW8 2/20 0.41
▸ CYP1A2 P05177 2/20 0.41
▸ CYP2D6 P10635 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4984176 0.93 TP53 (0.49) SMN1; SMN2TP53L3MBTL1SLC6A2SLC6A4
SCHEMBL9019184 0.90 SMN1; SMN2 (0.57) SMN1; SMN2L3MBTL1KMT2AOPRD1HTT
SCHEMBL4991700 0.90 SMN1; SMN2 (0.57) SMN1; SMN2L3MBTL1KMT2AOPRD1HTT
SCHEMBL14228916 0.88 GAA (0.44) SMN1; SMN2TP53L3MBTL1SLC6A2SLC6A4
SCHEMBL14228918 0.84 GAA (0.47) SMN1; SMN2SLC6A2SLC6A4NPSR1KMT2A
SCHEMBL22364647 0.83 SMN1; SMN2 (0.47) SMN1; SMN2KMT2AOPRD1HTTMEN1
SCHEMBL5664149 0.82 KDM4E (0.48) SMN1; SMN2TP53L3MBTL1KMT2AMEN1
SCHEMBL4986798 0.78 SMN1; SMN2 (0.44) SMN1; SMN2SLC6A2SLC6A4KMT2AMEN1
SCHEMBL5664937 0.78 KCNA5 (0.51) SMN1; SMN2TP53SLC6A2SLC6A4KMT2A
SCHEMBL12522057 0.78 GABBR2 (0.43) SMN1; SMN2NPSR1GAACYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040132745-A1 Microsomal triglyceride transfer protein inhibitor PFIZER INC 2004-07-08 — — US claimed
EP-1716137-A1 SUBSTITUTED QUINOLINE COMPOUNDS Pfizer Products Incorporated (US) 2006-11-02 — — EP disclosed
EP-1578725-A1 MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITORS Pfizer Products Inc. (US) 2005-09-28 — — EP disclosed
WO-2005080373-A1 SUBSTITUTED QUINOLINE COMPOUNDS PFIZER PRODUCTS INC. (US) 2005-09-01 — — WO disclosed
WO-2004056777-A1 MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITORS PFIZER PRODUCTS INC. (US) 2004-07-08 — — WO disclosed
US-20040132745-A1 Microsomal triglyceride transfer protein inhibitor PFIZER INC 2004-07-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040132745-A1 Microsomal triglyceride transfer protein inhibitor MTTP, CETP, APOB SMN1; SMN2 4591/4885TP53 4808/4885L3MBTL1 3319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback